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Abstract
Purpose: To construct a dose monitoring system based on an endorectal balloon coupled to thin scintillating fibers to study the
dose to the rectum in proton therapy of prostate cancer. Method: A Geant4 Monte Carlo toolkit was used to simulate the proton
therapy of prostate cancer, with an endorectal balloon and a set of scintillating fibers for immobilization and dosimetry meas-
urements, respectively. Results: A linear response of the fibers to the dose delivered was observed to within less than 2%. Re-
sults obtained show that fibers close to the prostate recorded higher dose, with the closest fiber recording about one-third of the
dose to the target. A 1/r2 (r is defined as center-to-center distance between the prostate and the fibers) decrease was observed as
one goes toward the frontal and distal regions. A very low dose was recorded by the fibers beneath the balloon which is a clear
indication that the overall volume of the rectal wall that is exposed to a higher dose is relatively minimized. Further analysis
showed a relatively linear relationship between the dose to the target and the dose to the top fibers (total 17), with a slope of
(-0.07 ± 0.07) at large number of events per degree of rotation of the modulator wheel (i.e., dose). Conclusion: Thin (1 mm × 1
mm), long (1 m) scintillating fibers were found to be ideal for real time in-vivo dose measurement to the rectum during proton
therapy of prostate cancer. The linear response of the fibers to the dose delivered makes them good candidates as dosimeters.
With thorough calibration and the ability to define a good correlation between the dose to the target and the dose to the fibers,
such dosimeters can be used for real time dose verification to the target.
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Introduction
Prostate cancer is the second leading cause of cancer related
death in men, with estimated deaths of about 29,720 for
2013.1-4 A number of treatment options are available for
prostate cancer patients. The most commonly used radiation
therapy modalities include: Brachytherapy implants5-7, in-
tensity modulated radiation therapy (IMRT)8-13, and proton
therapy.14-17 Due to the characteristic Bragg peak and physi-
cal properties of the proton beam, it possesses the ability to
penetrate deep before stopping in the medium.18 Sharp lat-
eral penumbra of the beam also allows sparing of the critical
structures adjacent to the tumor volume.19 The formation of
the Bragg peak in the depth dose distribution and the ability
to spread the dose out using a modulator wheel to generate a
spread out Bragg peak (SOBP) allows one to highly localize
the dose delivered to the target. This gives the advantage of
sparing much of the healthy tissue around the target, espe-
cially in the distal region. Hence, proton beam therapy is an
attractive option for the treatment of cancer. The ability to
geometrically conform the dose to the target, however,
should be accompanied with stringent requirements in the
target localization to avoid error in the dose delivered. The
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two main sources of uncertainties for this are patient setup
and organ motion. During prostate cancer therapy, bladder
and rectum emptying and/or filling are the main contribu-
tors to the organ motion.20, 21 Research studies showed that
such uncertainty can result in the introduction of prostate
displacement in the inferior-superior (IS), anterior-posterior
(AP), and right-left (RL) directions. Huang et al,13 for in-
stance, measured a maximum displacement in the AP (6.8
mm anteriorly to 4.6 mm posteriorly) and in the SI (3.5 mm
superiorly to 6.8 mm inferiorly) directions. Such displace-
ments are large enough to introduce a remarkable error in
the dose delivered to the prostate, especially when proton
beams are used to treat the tumor.
A number of techniques were devised to minimize the un-
certainty introduced by organ motion in the treatment of
prostate cancer. The use of an endorectal balloon, currently
practiced by a number of cancer centers, was found to great-
ly reduce the prostate motion by internally immobilizing
it.20, 22 This technique reduces the prostate displacement to
less than 1 mm according to the study results from McGary
et al.22 In addition to internally immobilizing the prostate,
researchers observed some additional benefits from the use
of an endorectal balloon. First, it reduces greatly the overall
volume of the rectal wall exposed to a higher dose.20, 23 Se-
cond, the balloon can be used to give a good prediction of
the prostate location.24 Most of the currently utilized bal-
loons have an embedded fiducial marker that can be easily
identified even in poor quality images. In the presence of a
good reproducibility in the placement of the balloon, since it
is also used during the simulation computed tomography
(CT) scan, fiducial markers (instead of bonny landmarks) can
be utilized for patient setup and prostate organ location.24
Third, some researchers took advantage of the use of an
endorectal balloon to develop an in-vivo dose measurement
tool for the rectum.25, 26 This can be performed by the use of
an appropriate dosimeters attached to the balloon to record
the dose at the surface of the balloon, which is in contact
with the inner rectal wall.
In this work, the Geant4 Monte Carlo toolkit27, 28 was used to
simulate the proton therapy of prostate cancer using an
endorectal balloon as an internal immobilization device.
Thin scintillating fibers were attached to the balloon for real
time in-vivo dose measurement to the surface of the balloon.
The characteristic properties that scintillating fibers possess
such as water equivalency, temperature and pressure inde-
pendence, fast response time etc. makes them ideal
dosimetric tools for this task.29 - 33 The fact that they can be
fabricated in any size and shape also makes them good can-
didates as they can be prepared in small sizes for a better
resolution. This can also make the fibers less intrusive as far
as the patient is concerned in clinical applications.
Methods and Materials
The Hadrontherapy Geant4 example application was used as
a reference to design the simulation described in this work.34
The modulator wheel that spreads out the Bragg peak to
generate an SOBP was modified to accommodate high ener-
gy proton beams. A spherical geometry of diameter 2.9 cm,
which is made up of a soft tissue equivalent material,
G4_TISSUE_SOFT_ICRP, obtained from the National Insti-
tute of Standards and Technology (NIST) database35, was
introduced to simulate the prostate. Geometries for the
endorectal balloon as well as the thin long scintillating fibers
(1 mm × 1 mm x 1 m) laying on the top surface and beneath
the balloon were also introduced and their placements are
detailed in Figure 2.
The beam line was designed with a simplified geometry to
mimic the beam line of the Hampton University Proton
Therapy Institute (HUPTI).36 Hence, a basic difference exists
between the beam line in the simulation design developed
and the one at HUPTI.
Results
The Geant4 based simulation developed was validated
against dedicated data acquired at HUPTI for a range of 257
mm and a modulation of 13 mm. The SOBP generated for a
200 MeV proton beam is compared to the measured data
from HUPTI in Figure 1 (arbitrary units were used to nor-
malize the data in the SOBP region).
The simulation data are in good agreement with the meas-
ured data. From Figure 1, the analysis of the data shows that
at the beginning of the SOBP and at the dose fall off regions,
the data points match within 4% and 3%, respectively. At
the end of the SOBP, however, there is a remarkable differ-
ence between the two data sets. This is due to the combined
effect of the beam line (differences in the geometry) and the
modulator wheel residual. At the distal 10% dose, a depth
difference of 2.5 mm was observed. The noticeable differ-
ence between the measured and the simulation data at the
entrance dose is due to the effect of the different amount of
secondary particles generated, a consequence of the beam
line discrepancy between the simplistic simulation and the
actual beam line at HUPTI.
In the simulation, a total of 34 fibers were placed around the
endorectal balloon for dosimetry (17 atop and 17 beneath).
The placement of the fibers around the balloon is shown in
Figure 2.
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FIG. 1: Comparison of the SOBP distribution from the Geant4 simulation and experimental data for a range of 257 mm and a modulation of 13
mm. The distributions are normalized in the SOBP region.
FIG. 2: The placement of the scintillating fibers around the balloon. The prostate is located on the top of the balloon, with the top fibers sand-
wiched in-between.
As shown in Figure 2, the fibers were laid on the surface of
the balloon, with the fiber ID running from 1 to 17 from left
to right. The beam direction is from left to right, irradiating
the whole prostate. At the end of the simulation run, the
energy deposited in all 34 fibers were recorded by requiring
a cut in the volume of interest. Therefore, the knowledge of
the geometrical location of each fiber is an important step.
To acquire such information, the beam propagation axis
(x-axis) was aligned with the center of the balloon. The plot
of the interaction points for the fibers in the Y-X (trans-
verse-longitudinal, cross sectional view) and Y-Z (transverse,
beam eye view) planes is shown in Figure 3.
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FIG. 3: The cross-sectional and beam eye view of the plot of the interaction points of the radiation in the top and bottom fibers.
The left panel of Figure 3 shows the cross-sectional view of
the 34 fibers around the balloon (17 top and 17 bottom),
with the beam momentum in the positive X direction. The X
(Xmin, Xmax) and Y (Ymin, Ymax) boundaries for each fiber were
extracted from the scatter distributions. The length of the
fibers along the surface of the balloon was acquired from the
readings of Zmin and Zmax. These six coordinate values gave
the volume of the individual fibers that are effectively col-
lecting the information on the surface of the balloon. These
values were subsequently used to calculate the energy de-
posited above and below the balloon.
In irradiating the prostate, 200 MeV protons were used with
the modulator wheel rotating from 00 to 3590 in steps of 10,
for a total 3600 to cover the entire prostate. The geometry for
the prostate was placed at a depth of 19.5 cm in a water filled
tank of 36 cm x 22 cm x 24 cm from the beam entrance sur-
face. The simulation was run for four different number of
events per degree of modulator wheel rotation: 500, 1000,
2000 and 3000 corresponding to a dose in µGy to the prostate
of 0.11, 0.21, 0.43, and 0.65, respectively. The total integrat-
ed energy deposited in each fiber inside the geometrical
volume of interest specified in Figure 3 was recorded and is
plotted in Figure 4.
The energy deposited in the bottom fibers, which corre-
sponds to the inner posterior wall of the rectum, was negli-
gibly small compared to the energy deposited in the top fi-
bers as well as inside the prostate: the maximum value rec-
orded was 3.99 MeV for the central and for the 3000 events
per degree of modulator rotation run. The energy deposited
in the prostate as well as the total energy deposited in the
top 17 fibers are given in Table 1. The table also shows the
number of protons delivered in each setup. One can observe
that the number of protons used is very small compared to
the number required in the clinic to deliver a dose of 1.8
Cobalt Gray Equivalent (CGE) to a Kg of water, which is of
the order of 1010. This is the dose per fraction most of the
time prescribed for prostate cancer patients at HUPTI. In the
simulation, the dose delivered was of the order of a few μGy
due to computational limitations.
Number of events
Per degree
Total number of events
(protons)
Total energy deposited in
the prostate (MeV)
Total energy deposited in the top
fibers (MeV)
500 1.80 X 105 8,696.22 111.51
1000 3.60 X 105 16,667.64 263.73
2000 7.20 X 105 34,381.29 504.38
3000 1.08 X 106 51,881.16 812.04
TABLE 1: Energy deposited in the prostate and the top 17 fibers during the irradiation of the prostate for the four different settings used in the
Geant4 simulation.
The calculation of the energy deposited per unit volume
(MeV/cc) gave 4062 and 1214 for the prostate and the top
middle fiber (Fiber ID 9), respectively. These correspond to
an absorbed dose of 0.65 μGy and 0.19 μGy for the prostate
and the fiber, respectively. This result showed that the sec-
tion of the rectal wall represented by Fiber ID 9 is pushed by
the inflated balloon to the high dose region, receiving about
a third of the dose deposited in the prostate. As one moves
away from the middle fiber towards the frontal and distal
regions, the value of the energy deposited per unit volume
decreases dramatically. For Fiber ID 1 (frontal region) and
Fiber ID 17 (distal region) the values were 517 (factor of 1/8)
and 428 (factor of 1/9), respectively, corresponding to an
absorbed dose of approximately 0.08 μGy and 0.07 μGy to
the frontal and distal fibers, respectively. In the actual
treatment of a prostate cancer patient, the anterior section of
Volume 2 • Number 2 • 2014 International Journal of Cancer Therapy and Oncology 5
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the rectal wall is usually included in the PTV. Consequently,
the top Fiber ID 9 will be inside the PTV, receiving the pre-
scribed dose. Hence, this fiber can be used for real time dose
verification to the PTV during irradiation. In the simulation,
however, all the top fibers were kept outside of the field, a
reason for the absorbed dose to be lower for the fibers than
that of the prostate. Similar results were obtained for the
other simulation runs. The corresponding plot of the energy
deposited versus the Fiber IDs is shown in Figure 4. The
energy deposited as a function of the number of events per
degree of modulator rotation (i.e., dose), for the prostate and
the total energy deposited to the 17 top fibers, is shown in
Figure 5.
FIG. 4: A plot of the energy deposited in the top fibers as a function of the fiber ID for the different number of events per degree of modulator
wheel rotation.
FIG. 5: A plot of the total energy deposited in the top 17 fibers as well as in the prostate as a function of the events per degree of rotation (i.e.,
dose). The ratio of the energy deposited in the prostate to the total energy in the top 17 fibers is also shown. The energy in the prostate is scaled
down by 0.05, while the ratio is scaled up by 20 for clarity.
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Discussion
From the results obtained, one observes that increasing the
number of events per degree of rotation (i.e., dose) increases
the energy deposited inside the fibers. In Figure 4, it can be
observed that the energy deposited is largest around the
middle fibers, especially for the central (Fiber ID 9), which is
the closest to the prostate. In moving to the frontal (Fiber ID
1) and distal (Fiber ID 17) regions, the energy deposited de-
creases as 1/r2 (r is defined as center-to-center distance be-
tween prostate and fiber), which implies that the overall
rectal wall volume exposed to higher radiation is smaller.
This result is in good agreement to the results obtained by
other researchers.20, 23 In the actual planning of the treat-
ment, the top section of the rectum is usually enclosed
within the planning target volume (PTV). Hence, the Fiber
ID 9, located at the top middle, is usually enclosed within
the PTV receiving the prescribed dose. With appropriate
calibration, this fiber can be used to monitor the dose deliv-
ered to the PTV.
Further analysis of the data showed that there is also a linear
response of the scintillating fibers to the radiation dose de-
livered to the prostate, with a precision of less than 2% as
show in Figure 5: slope of 0.853±0.077 MeV/events per
degree for the prostate and 0.275±0.023 MeV/events per
degree for the fibers. This result is one of the characteristic
properties studied by a number of other researchers that
make the fibers ideal as a dosimetric tool.29- 33 Moreover, the
ratio of the energy deposited in the prostate to the total en-
ergy deposited in the top 17 fibers gets relatively constant,
especially for larger number of events (slope of -0.07±0.07
MeV per Gy to the prostate). Once a clear relationship is
defined between the dose to the prostate and the dose to the
fibers, those fibers can be used as dose verification tools to
the target.
Conclusion
In this work, the use of an endorectal balloon coupled to
thin scintillating fibers was studied as a potential dose moni-
toring system in proton therapy of prostate cancer. Based on
the results obtained, the energy deposited in the fibers
placed atop the balloon was observed to decrease as 1/r2 as
one goes to the distal and proximal ends from the central
fiber. In addition, the total energy deposited inside the 17
fibers located beneath the balloon near the posterior section
of the rectal wall was 0.27% of the energy deposited in the
top middle fiber (Fiber ID 9) alone. These results indicate
that the top section of the rectal wall is pushed to the high
dose region while the overall volume of the rectal wall ex-
posed to a higher dose is very small. Further analysis of the
data shows that the ratio of the dose deposited in the pros-
tate to the total dose deposited in the top 17 fibers is rela-
tively flat with a slope of -0.07±0.07, especially at large
number of events. Hence, with appropriate calibration, these
fibers can be used to give a precise prediction of the dose
delivered to the prostate, opening the capability of an
in-vivo dose monitoring system during irradiation. An ex-
perimental setup will be designed based on the simulation
presented herein. The results will be presented in a forth-
coming paper.
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